Literature DB >> 25585942

Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.

A S C Conlon1, J M G Taylor1, D J Sargent2.   

Abstract

In clinical trials, an intermediate marker measured after randomization can often provide early information about the treatment effect on the final outcome of interest. We explore the use of recurrence time as an auxiliary variable for estimating the treatment effect on overall survival in phase three randomized trials of colon cancer. A multi-state model with an incorporated cured fraction for recurrence is used to jointly model time to recurrence and time to death. We explore different ways in which the information about recurrence time and the assumptions in the model can lead to improved efficiency. Estimates of overall survival and disease-free survival can be derived directly from the model with efficiency gains obtained as compared to Kaplan-Meier estimates. Alternatively, efficiency gains can be achieved by using the model in a weaker way in a multiple imputation procedure, which imputes death times for censored subjects. By using the joint model, recurrence is used as an auxiliary variable in predicting survival times. We demonstrate the potential use of the proposed methods in shortening the length of a trial and reducing sample sizes.
© 2015, The International Biometric Society.

Entities:  

Keywords:  Auxiliary variable; Colon cancer; Cure models; Multi-state model; Multiple imputation

Mesh:

Year:  2015        PMID: 25585942      PMCID: PMC4480062          DOI: 10.1111/biom.12281

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  11 in total

1.  A measure of the proportion of treatment effect explained by a surrogate marker.

Authors:  Yue Wang; Jeremy M G Taylor
Journal:  Biometrics       Date:  2002-12       Impact factor: 2.571

2.  Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective.

Authors:  Ariel Alonso; Geert Molenberghs
Journal:  Stat Methods Med Res       Date:  2008-02-19       Impact factor: 3.021

3.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

4.  Using auxiliary variables for improved estimates of survival time.

Authors:  S W Lagakos
Journal:  Biometrics       Date:  1977-06       Impact factor: 2.571

5.  Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.

Authors:  Anna S C Conlon; Jeremy M G Taylor; Daniel J Sargent; Greg Yothers
Journal:  Clin Trials       Date:  2011-09-15       Impact factor: 2.486

6.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.

Authors:  T R Fleming; R L Prentice; M S Pepe; D Glidden
Journal:  Stat Med       Date:  1994-05-15       Impact factor: 2.373

7.  Analysing survival in the presence of an auxiliary variable.

Authors:  D M Finkelstein; D A Schoenfeld
Journal:  Stat Med       Date:  1994-09-15       Impact factor: 2.373

8.  A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials.

Authors:  Yun Li; Jeremy M G Taylor; Roderick J A Little
Journal:  Biometrics       Date:  2011-05-31       Impact factor: 2.571

9.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

10.  Multi-state models for colon cancer recurrence and death with a cured fraction.

Authors:  A S C Conlon; J M G Taylor; D J Sargent
Journal:  Stat Med       Date:  2013-12-05       Impact factor: 2.373

View more
  4 in total

1.  Assessing survival benefit when treatment delays disease progression.

Authors:  David A Schoenfeld; Dianne M Finkelstein
Journal:  Clin Trials       Date:  2016-02-22       Impact factor: 2.486

2.  A Bayesian multi-risks survival (MRS) model in the presence of double censorings.

Authors:  Mário de Castro; Ming-Hui Chen; Yuanye Zhang; Anthony V D'Amico
Journal:  Biometrics       Date:  2020-02-06       Impact factor: 2.571

3.  A note on compatibility for inference with missing data in the presence of auxiliary covariates.

Authors:  Michael J Daniels; Xuan Luo
Journal:  Stat Med       Date:  2018-11-18       Impact factor: 2.373

4.  Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer.

Authors:  G Manzini; T J Ettrich; M Kremer; M Kornmann; D Henne-Bruns; D A Eikema; P Schlattmann; L C de Wreede
Journal:  BMC Med Res Methodol       Date:  2018-02-13       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.